Efficacy of Alogliptin and Pioglitazone in Subjects With Type 2 Diabetes Mellitus

PHASE3CompletedINTERVENTIONAL
Enrollment

803

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

May 31, 2009

Study Completion Date

June 30, 2009

Conditions
Diabetes Mellitus
Interventions
DRUG

Alogliptin

Alogliptin tablets.

DRUG

Pioglitazone

Pioglitazone tablets.

DRUG

Metformin

Metformin HCl tablets (immediate-release, commercially available formulation) ≥1500 mg or maximum tolerated dose.

DRUG

Placebo

Matching placebo tablets.

Trial Locations (86)

Unknown

Birmingham

Huntsville

Lake Havasu City

Little Rock

Foothill Ranch

Los Alamitos

Los Angeles

Pismo Beach

San Diego

Golden

Clearwater

Hialeah

Lakeland

Marianna

Miami

North Miami Beach

Pembroke Pines

Sebastian

South Miami

Tampa

Winter Park

Blue Ridge

Conyers

Decatur

Duluth

Dunwoody

Warner Robins

Boise

Coeur d'Alene

Burr Ridge

Chicago

Melrose Park

Naperville

O'Fallon

Bloomington

Mishawaka

Overland Park

Marrero

Elkton

Rockville

Towson

Marlborough

Bay City

Saint Clair Shores

McCook

Las Vegas

Blackwood

Trenton

West Caldwell

Asheboro

Charlotte

Mooresville

Shelby

Sparta

Bismarck

Orrville

Norman

Ashland

Aliquippa

Altoona

Dawningtown

Fleetwood

Kingston

Norristown

Pittsburgh

Tipton

Florence

Taylors

Williamston

Watertown

Kingsport

Milan

Nashville

Arlington

Austin

Colleyville

El Paso

Garland

Houston

Hurst

San Antonio

Seguin

Hampton

Norfolk

Richmond

Virginia Beach

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Takeda

INDUSTRY

NCT00432276 - Efficacy of Alogliptin and Pioglitazone in Subjects With Type 2 Diabetes Mellitus | Biotech Hunter | Biotech Hunter